UNI2

UNI2 (also referred to as UNI-2) is a pharmaceutical-grade medical cannabis formulation developed by Univo Pharmaceuticals. It is specifically designed as a standardized cannabinoid-based therapy intended for the management of chronic pain conditions, with a primary focus on fibromyalgia. The drug leverages a specific ratio of cannabinoids, such as THC and CBD, to target the endocannabinoid system, aiming to modulate pain signaling and inflammatory responses. By providing a consistent and controlled dosage form, UNI2 seeks to offer a reliable alternative to conventional analgesics for patients suffering from centralized pain syndromes where traditional treatments often prove inadequate.